Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Nimotuzumab Plus Docetaxel in Chemotherapy-refractory/Resistant Patients With Advanced Non-small-cell Lung Cancer

NCT00983047 is registered in ClinicalTrials.gov with Biotech Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT00983047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00983047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Nimotuzumab Plus Docetaxel in Chemotherapy-refractory/Resistant Patients With Advanced Non-small-cell Lung Cancer
Lead sponsor
Biotech Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2009
Completion date
August 31, 2015
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small cell lung cancer